Huntington's disease (HD) is a progressive neurodegenerative disorder primarily affecting the basal ganglia and is caused by expanded CAG repeats in the huntingtin gene. Except for CAG sizing, mitochondrial and nuclear DNA (mtDNA and nDNA) parameters have not yet proven to be representative biomarkers for disease and future therapy. Here, we identified a general suppression of genes associated with aerobic metabolism in peripheral blood mononuclear cells (PBMCs) from HD patients compared to controls. In HD, the complex II subunit SDHB was lowered although not sufficiently to affect complex II activity. Nevertheless, we found decreased level of factors associated with mitochondrial biogenesis and an associated dampening of the mitochondrial DNA damage frequency in HD, implying an early defect in mitochondrial activity. In contrast to mtDNA, nDNA from HD patients was four-fold more modified than controls and demonstrated that nDNA integrity is severely reduced in HD. Interestingly, the level of nDNA damage correlated inversely with the total functional capacity (TFC) score; an established functional score of HD. Our data show that PBMCs are a promising source to monitor HD progression and highlights nDNA damage and diverging mitochondrial and nuclear genome responses representing early cellular impairments in HD.

Department of Medical Biochemistry Institute of Clinical Medicine University of Oslo Oslo Norway

Department of Microbiology Oslo University Hospital Oslo Norway

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Department of Pediatrics and Adolescent Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Proteomics and Metabolomics Core Facility PROMEC Department of Clinical and Molecular Medicine Norwegian University of Science and Technology Trondheim Norway

Zobrazit více v PubMed

Adegbuyiro A, Sedighi F, Pilkington AWT, Groover S, Legleiter J. Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease. Biochemistry. 2017;56:1199–1217. doi: 10.1021/acs.biochem.6b00936. PubMed DOI PMC

Duyao MP, et al. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science. 1995;269:407–410. doi: 10.1126/science.7618107. PubMed DOI

Nasir J, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81:811–823. doi: 10.1016/0092-8674(95)90542-1. PubMed DOI

Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat Genet. 1995;11:155–163. doi: 10.1038/ng1095-155. PubMed DOI

Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord11, 136–142, 10.1002/mds.870110204 (1996). PubMed

Losekoot M, et al. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet. 2013;21:480–486. doi: 10.1038/ejhg.2012.200. PubMed DOI PMC

Aylward, E. H. et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord15, 552–560, https://doi.org/10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P (2000). PubMed

Paulsen JS, et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874–880. doi: 10.1136/jnnp.2007.128728. PubMed DOI PMC

Klempir J, Klempirova O, Spackova N, Zidovska J, Roth J. Unified Huntington’s disease rating scale: clinical practice and a critical approach. Funct Neurol. 2006;21:217–221. PubMed

Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet. 1985;27:62–67. doi: 10.1111/j.1399-0004.1985.tb00185.x. PubMed DOI

Busse ME, Hughes G, Wiles CM, Rosser AE. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington’s disease. J Neurol. 2008;255:1534–1540. doi: 10.1007/s00415-008-0964-x. PubMed DOI

Borovecki F, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci USA. 2005;102:11023–11028. doi: 10.1073/pnas.0504921102. PubMed DOI PMC

Mihm MJ, et al. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2007;25:297–308. doi: 10.1016/j.nbd.2006.09.016. PubMed DOI PMC

Sawa A, et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999;5:1194–1198. doi: 10.1038/13518. PubMed DOI

Squitieri F, et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev. 2006;127:217–220. doi: 10.1016/j.mad.2005.09.010. PubMed DOI

Almeida S, Sarmento-Ribeiro AB, Januario C, Rego AC, Oliveira CR. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington’s disease patients. Biochem Biophys Res Commun. 2008;374:599–603. doi: 10.1016/j.bbrc.2008.07.009. PubMed DOI

Liu X, Luo X, Hu W. Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed Environ Sci. 1992;5:161–177. PubMed

Lin CH, et al. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet. 2001;10:137–144. doi: 10.1093/hmg/10.2.137. PubMed DOI

Weydt P, et al. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab. 2006;4:349–362. doi: 10.1016/j.cmet.2006.10.004. PubMed DOI

Damiano M, et al. A role of mitochondrial complex II defects in genetic models of Huntington’s disease expressing N-terminal fragments of mutant huntingtin. Hum Mol Genet. 2013;22:3869–3882. doi: 10.1093/hmg/ddt242. PubMed DOI PMC

Panov AV, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5:731–736. doi: 10.1038/nn884. PubMed DOI

Kovtun IV, et al. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature. 2007;447:447–452. doi: 10.1038/nature05778. PubMed DOI PMC

Mollersen L, et al. Neil1 is a genetic modifier of somatic and germline CAG trinucleotide repeat instability in R6/1 mice. Hum Mol Genet. 2012;21:4939–4947. doi: 10.1093/hmg/dds337. PubMed DOI PMC

Manley K, Shirley TL, Flaherty L, Messer A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet. 1999;23:471–473. doi: 10.1038/70598. PubMed DOI

Wheeler VC, et al. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet. 2003;12:273–281. doi: 10.1093/hmg/ddg056. PubMed DOI

Budworth H, et al. Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington’s Disease. PLoS Genet. 2015;11:e1005267. doi: 10.1371/journal.pgen.1005267. PubMed DOI PMC

Wang W, et al. Mitochondrial DNA integrity is essential for mitochondrial maturation during differentiation of neural stem cells. Stem Cells. 2010;28:2195–2204. doi: 10.1002/stem.542. PubMed DOI

Pawar, T., Bjoras, M., Klungland, A. & Eide, L. Metabolism and DNA repair shape a specific modification pattern in mitochondrial DNA. Mitochondrion, 10.1016/j.mito.2017.09.002 (2017). PubMed

Bae BI, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington’s disease. Neuron. 2005;47:29–41. doi: 10.1016/j.neuron.2005.06.005. PubMed DOI

Wang W, Scheffler K, Esbensen Y, Eide L. Quantification of DNA Damage by Real-Time qPCR. Methods Mol Biol. 2016;1351:27–32. doi: 10.1007/978-1-4939-3040-1_3. PubMed DOI

Disatnik MH, et al. Potential biomarkers to follow the progression and treatment response of Huntington’s disease. J Exp Med. 2016;213:2655–2669. doi: 10.1084/jem.20160776. PubMed DOI PMC

Browne SE, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41:646–653. doi: 10.1002/ana.410410514. PubMed DOI

Chen CM, et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun. 2007;359:335–340. doi: 10.1016/j.bbrc.2007.05.093. PubMed DOI

Borowsky B, et al. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. 2013;80:1934–1941. doi: 10.1212/WNL.0b013e318293e1a1. PubMed DOI PMC

Levada-Pires AC, et al. The effect of an adventure race on lymphocyte and neutrophil death. Eur J Appl Physiol. 2010;109:447–453. doi: 10.1007/s00421-010-1363-4. PubMed DOI

Jedrak P, et al. Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts. Metab Brain Dis. 2017;32:1237–1247. doi: 10.1007/s11011-017-0026-0. PubMed DOI PMC

Lagouge M, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122. doi: 10.1016/j.cell.2006.11.013. PubMed DOI

Mejia EM, Chau S, Sparagna GC, Sipione S, Hatch GM. Reduced Mitochondrial Function in Human Huntington Disease Lymphoblasts is Not Due to Alterations in Cardiolipin Metabolism or Mitochondrial Supercomplex Assembly. Lipids. 2016;51:561–569. doi: 10.1007/s11745-015-4110-0. PubMed DOI

Pawar T, Eide L. Pitfalls in mitochondrial epigenetics. Mitochondrial DNA A DNA Mapp Seq Anal. 2017;28:762–768. PubMed

Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington’s disease (HD) Cell Cycle. 2015;14:1716–1729. doi: 10.1080/15384101.2015.1033595. PubMed DOI PMC

Scheffler K, et al. 8-oxoguanine DNA glycosylase (Ogg1) controls hepatic gluconeogenesis. DNA Repair (Amst) 2018;61:56–62. doi: 10.1016/j.dnarep.2017.11.008. PubMed DOI

Vartanian V, et al. The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci USA. 2006;103:1864–1869. doi: 10.1073/pnas.0507444103. PubMed DOI PMC

Prokesch A, et al. Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis. FASEB J. 2017;31:732–742. doi: 10.1096/fj.201600845R. PubMed DOI PMC

Maranzana E, Barbero G, Falasca AI, Lenaz G, Genova ML. Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. Antioxid Redox Signal. 2013;19:1469–1480. doi: 10.1089/ars.2012.4845. PubMed DOI PMC

Strand JM, Scheffler K, Bjoras M, Eide L. The distribution of DNA damage is defined by region-specific susceptibility to DNA damage formation rather than repair differences. DNA Repair (Amst) 2014;18:44–51. doi: 10.1016/j.dnarep.2014.03.003. PubMed DOI

Gu M, et al. Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol. 1996;39:385–389. doi: 10.1002/ana.410390317. PubMed DOI

Arenas J, et al. Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol. 1998;43:397–400. doi: 10.1002/ana.410430321. PubMed DOI

Tabrizi SJ, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000;47:80–86. doi: 10.1002/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K. PubMed DOI

Kaarbo M, et al. Human cytomegalovirus infection increases mitochondrial biogenesis. Mitochondrion. 2011;11:935–945. doi: 10.1016/j.mito.2011.08.008. PubMed DOI

Sharma S, Wang J, Cortes Gomez E, Taggart RT, Baysal BE. Mitochondrial complex II regulates a distinct oxygen sensing mechanism in monocytes. Hum Mol Genet. 2017;26:1328–1339. doi: 10.1093/hmg/ddx041. PubMed DOI PMC

Hensman Moss DJ, et al. Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays. PLoS One. 2017;12:e0189891. doi: 10.1371/journal.pone.0189891. PubMed DOI PMC

Chang KH, Wu YR, Chen YC, Chen CM. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav Immun. 2015;44:121–127. doi: 10.1016/j.bbi.2014.09.011. PubMed DOI

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. PubMed DOI

Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166:368–379. doi: 10.1016/0003-2697(87)90587-2. PubMed DOI

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275. PubMed

Honzik T, et al. Activities of respiratory chain complexes and pyruvate dehydrogenase in isolated muscle mitochondria in premature neonates. Early Hum Dev. 2008;84:269–276. doi: 10.1016/j.earlhumdev.2006.07.008. PubMed DOI

Fornuskova D, et al. Novel insights into the assembly and function of human nuclear-encoded cytochrome c oxidase subunits 4, 5a, 6a, 7a and 7b. Biochem J. 2010;428:363–374. doi: 10.1042/BJ20091714. PubMed DOI

Srere PA, John ML. Citrate synthase: [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)] Methods in Enzymology. 1969;ume 13:8.

Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes

Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease

A transgenic minipig model of Huntington's disease shows early signs of behavioral and molecular pathologies